MRX-5 / MicuRx - LARVOL DELTA

In vitro and In vivo activity of a novel Leucyl-tRNA synthetase inhibitor against Mycobacterium abscessus (WBC 2024) - "BALB/c mice rendered neutropenic with intraperitoneal cyclophosphamide were infected through nasal instillation with M. abscessus ~106 CFU/mouse...When MRX-6038 was combined with clarithromycin, rifabutin, amikacin, and ethambutol, the resistance frequency was greatly reduced to below 2.9 × 10-10... MRX-6038 and its oral prodrug MRX-5 demonstrated potent activity against M. abscessus in in vitro and in vivo animal infection studies. Further investigation is warranted for the development of MRX-6038/MRX-5 as treatment for MABC-PD."

Preclinical • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases

11 Class 1 innovative drugs were approved for clinical trials in China for the first time!… [Google translation] (Sina Corp) - "Mengke Pharmaceuticals' Class 1 new drug MRX-5 tablets have been approved for clinical trials. The product is intended to treat infections caused by nontuberculous mycobacteria (NTM) that are sensitive to this product...Beite Pharmaceuticals' Class 1 new drug BPR-30221616 injection has been approved for clinical trials and is intended to be developed to treat transthyretin amyloid cardiomyopathy...The Class 1 new drug CM559 injection applied by Conoya has been approved for clinical trials and is intended to be developed to treat Alzheimer's disease...The Class 1 new drug ART101 injection filed by Ontop Biopharmaceuticals has been approved for clinical trials and is intended to be developed for the treatment of hypertension....Sanofi 's Class 1 new drug SAR442970 injection has been approved for clinical use and is intended to treat primary focal segmental glomerulosclerosis (FSGS) or primary minimal change nephropathy (MCD) in adults and adolescents aged 16 and above."

New trial • Alzheimer's Disease • Cardiomyopathy • Focal Segmental Glomerulosclerosis • Hypertension • Nontuberculous Mycobacterial Disease

FDA Grants Orphan Drug Designation to MicuRx’s MRX-5 for NTM Infections (MicuRx Press Release) - "Shanghai MicuRx Pharmaceutical Co., Ltd...announced that MRX-5, its self-developed anti-infection drug, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of non-tuberculous mycobacteria (NTM) infections."

Orphan drug • Nontuberculous Mycobacterial Disease